Wockhardt Ltd
WOCKPHARMAWockhardt Ltd
WOCKPHARMA![](https://assets.tickertape.in/sector-icons/health_care.png)
![](https://assets.tickertape.in/sector-icons/smallcap.png)
![](https://assets.tickertape.in/sector-icons/high_risk.png)
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
-28.52 | 3.61 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
46.01 | 6.09 | 0.55% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Wockhardt Limited manufactures and markets pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Zydus Lifesciences Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 4,519.32 | 4,128.86 | 4,057.13 | 3,681.99 | 2,977.36 | 3,825.00 | 3,250.00 | 2,773.00 | 2,881.00 | 2,898.00 | ||||||||||
Raw Materials | 1,678.09 | 1,687.94 | 1,619.00 | 1,605.85 | 1,129.42 | 1,262.00 | 1,180.00 | 1,027.00 | 1,179.00 | 2,790.00 | ||||||||||
Power & Fuel Cost | 113.99 | 110.10 | 77.80 | 93.30 | 85.41 | 82.00 | 98.00 | 103.00 | 107.00 | |||||||||||
Employee Cost | 950.77 | 966.51 | 937.06 | 800.38 | 743.33 | 763.00 | 749.00 | 637.00 | 629.00 | |||||||||||
Selling & Administrative Expenses | 660.85 | 709.73 | 684.13 | 554.77 | 327.73 | 383.00 | 404.00 | 326.00 | 313.00 | |||||||||||
Operating & Other expenses | 555.28 | 527.53 | 975.27 | 550.02 | 439.07 | 423.00 | 684.00 | 751.00 | 545.00 | |||||||||||
EBITDA | 560.34 | 127.05 | -236.13 | 77.67 | 252.40 | 912.00 | 135.00 | -71.00 | 108.00 | 108.00 | ||||||||||
Depreciation/Amortization | 141.91 | 148.93 | 149.53 | 163.95 | 224.14 | 246.00 | 247.00 | 251.00 | 223.00 | 223.00 | ||||||||||
PBIT | 418.43 | -21.88 | -385.66 | -86.28 | 28.26 | 666.00 | -112.00 | -322.00 | -115.00 | -115.00 | ||||||||||
Interest & Other Items | 128.96 | 225.27 | 255.49 | 265.14 | 275.74 | 249.00 | 299.00 | 302.00 | 305.00 | 305.00 | ||||||||||
PBT | 289.47 | -247.15 | -641.15 | -351.42 | -247.48 | 417.00 | -411.00 | -624.00 | -420.00 | -420.00 | ||||||||||
Taxes & Other Items | 38.75 | -51.43 | -32.85 | -156.89 | -178.26 | -269.00 | -167.00 | -65.00 | 43.00 | 43.00 | ||||||||||
Net Income | 250.72 | -195.72 | -608.30 | -194.53 | -69.22 | 686.00 | -244.00 | -559.00 | -463.00 | -463.00 | ||||||||||
EPS | 20.95 | -16.32 | -50.69 | -16.20 | -5.76 | 57.08 | -18.47 | -38.80 | -31.13 | -30.18 | ||||||||||
DPS | 0.00 | 9.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Wockhardt Ltd | -28.52 | 3.61 | — |
Sun Pharmaceutical Industries Ltd | 41.74 | 5.96 | 0.81% |
Zydus Lifesciences Ltd | 31.44 | 5.49 | 0.25% |
Cipla Ltd | 29.39 | 5.11 | 0.87% |
Price Comparison
Compare WOCKPHARMA with any stock or ETFShareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
In last 6 months, promoter holding in the company has decreased by 2.94%
High Pledged Promoter Holding
A significant proportion of promoter holdings is pledged
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Wockhardt Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
ICICI Prudential Equity & Debt Fund - Direct Plan - Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3666% | Percentage of the fund’s portfolio invested in the stock 0.14% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 117/178 (+5) |
Invesco India Smallcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3346% | Percentage of the fund’s portfolio invested in the stock 0.96% | Change in the portfolio weight of the stock over the last 3 months 0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 66/80 (-3) |
Samco Active Momentum Fund - Direct Plan - Growth Option Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3257% | Percentage of the fund’s portfolio invested in the stock 5.60% | Change in the portfolio weight of the stock over the last 3 months 0.39% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 2/66 (+2) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
WOCKPHARMA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateNov 17, 2016
Dividend/Share
₹10.00
Ex DateEx Date
Nov 17, 2016
Cash Dividend
Ex DateEx DateNov 13, 2014
Dividend/Share
₹20.00
Ex DateEx Date
Nov 13, 2014
Cash Dividend
Ex DateEx DateFeb 17, 2014
Dividend/Share
₹5.00
Ex DateEx Date
Feb 17, 2014
Cash Dividend
Ex DateEx DateNov 7, 2013
Dividend/Share
₹5.00
Ex DateEx Date
Nov 7, 2013
Cash Dividend
Ex DateEx DateAug 22, 2013
Dividend/Share
₹5.00
Ex DateEx Date
Aug 22, 2013
Mumbai Medical Miracle: Docs At Wockhardt Hospital Remove Over 7 Centimeters Long & Rare Non-Cancerous Tumour From 63-Year-Old Woman’s Nose
![](https://pocket-image-cache.com/direct?url=http://media.assettype.com/freepressjournal/2024-07/5b550f5f-30f0-4658-8337-3aa8cbf8c57a/Untitled%20design%20(98).jpg)
Mumbai: 42-Year-Old Saved From Ruptured Brain Aneurysm Through Advanced Endovascular Treatment at Wockhardt Hospital
![](https://pocket-image-cache.com/direct?url=http://media.assettype.com/freepressjournal/2024-07/a91e7127-bef5-4730-a976-213388e517ed/Wockhardt%20Hospital.jpg)
Pharma shares shine; Dr Reddy’s, FDC, Glenmark, Suven trade at record highs
![](https://pocket-image-cache.com/direct?url=http://bsmedia.business-standard.com/_media/bs/img/article/2024-03/07/thumb/featurecrop/400X400/1709750255-5349.jpg)
Wockhardt enters last mile to bring two of its promising antibiotics to India
Wockhardt Ltd leads gainers in ‘A’ group
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
Wockhardt soars as Zaynich shows promise against superbugs
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
Mumbai-based Wockhardt to launch its novel antibiotic Zaynich by FY25-end
![](https://pocket-image-cache.com/direct?url=http://bsmedia.business-standard.com/_media/bs/img/article/2024-03/07/thumb/featurecrop/400X400/1709750255-5349.jpg)
Wockhardt Launches New Antibiotic With $25-Billion Market Potential
![](https://pocket-image-cache.com/direct?url=http://media.assettype.com/bloombergquint%2F2022-07%2F20547a5c-2073-4b60-94b2-641b2ad27d27%2Fchristina_victoria_craft_ZHys6xN7sUE_unsplash.jpg?rect=0%2C652%2C6016%2C3158&w=1200&auto=format%2Ccompress&ogImage=true)
![](https://i2.ytimg.com/vi/1jk26EHVQPI/hqdefault.jpg)
Wockhardt Shares Locked In 5% Upper Circuit After Raising Rs 480 Crore Via QIP
![](https://pocket-image-cache.com/direct?url=http://media.assettype.com/bloombergquint%2F2024-03%2Fcc42f773-18bc-4109-97f9-ad48c252b699%2FUSA_MGP_2000x1200.jpg?rect=0%2C150%2C2000%2C1050&w=1200&auto=format%2Ccompress&ogImage=true)
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of -4.79%, vs industry avg of 8.96%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.63% to 0.78%